Clinical Trial Update: A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) [Phase 3]

View source ↗

Summary

A Phase 3 trial named EVOKE evaluated semaglutide in people with early Alzheimer's disease and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• semaglutide (semaglutide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Early Alzheimer's Disease | Phase 3 | Status: COMPLETED